ArticleAntibiotics (Basel, Switzerland)2018
Combatting Antibiotic Resistance Together: How Can We Enlist the Help of Industry?
Article in Antibiotics (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Identification, mapping, and self-reported practice patterns of village doctors in Sitakunda subdistrict, Bangladesh.Journal of global health · 2024Article
- Prescribing antibiotics prudently-A survey of policy implementation drivers among physicians and veterinarians.One health (Amsterdam, Netherlands) · 2024Article
- Balancing the risks and benefits of antibiotic use in a globalized world: the ethics of antimicrobial resistance.Globalization and health · 2023Article
- Chitosan Nanoparticle Encapsulation of Antibacterial Essential Oils.Micromachines · 2022Review
- What are the challenges for antibiotic stewardship at the community level? An analysis of the drivers of antibiotic provision by informal healthcare providers in rural India.Social science & medicine (1982) · 2021Article
- Antibiotic Resistance: One Health One World Outlook.Frontiers in cellular and infection microbiology · 2021Review
- Assessing Upstream Determinants of Antibiotic Use in Small-Scale Food Animal Production through a Simulated Client Method.Antibiotics (Basel, Switzerland) · 2020Article
- Microbial Resistance Movements: An Overview of Global Public Health Threats Posed by Antimicrobial Resistance, and How Best to Counter.Frontiers in public health · 2020Review
- Challenges in Implementing Antimicrobial Stewardship Programmes at Secondary Level Hospitals in India: An Exploratory Study.Frontiers in public health · 2020Article
- Global Internet Data on the Interest in Antibiotics and Probiotics Generated by Google Trends.Antibiotics (Basel, Switzerland) · 2019Article
- Stable Redox-Cycling Nitroxide Tempol Has Antifungal and Immune-Modulatory Properties.Frontiers in microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The development of antibiotics needs to be supported through new financial stimuli, including help from the public sector. In exchange for public support, industry should be asked to do what is in their power to help curb the inappropriate use of antibiotics. This work discusses key areas through which industry has an important influence on antibiotic consumption and where agreements can be made alongside financial incentives, even those intended to stimulate very early research. As long as the traditional unit sale-based business model for antibiotics remains in place, profit-making incentives will likely undermine efforts to sell and utilize antibiotics in a sustainable manner. In the short-term, while we try to come to a consensus on how best to fix the market, we need measures to prevent major over-selling and inappropriate promotion-especially for new, badly needed antibiotics that reach the market. This paper explores ways in which the pharmaceutical industry could help buttress sustainable antibiotic use while we search for more long-term, constructive, mutually-beneficial ways to organize the market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.